Dr. Arlene Sharpe on the Discovery and Further Use of the PD-L1 Pathway

Arlene Sharpe, MD, PhD

Sharpe, whose lab aided in the discover of the pathway, says blocking the pathway in order to treat cancers is important because it allows T cells to work better.

Arlene Sharpe, MD, PhD, immunology faculty member, Harvard Medical School, discusses the discovery of the PD-L1 pathway and the importance of the pathway in inhibiting anti-tumor immunity. Sharpe, whose lab aided in the discover of the pathway, says blocking the pathway in order to treat cancers is important because it allows T cells to work better.

Sharpe adds that the pathway was initially tested in both melanoma and lung cancer, which proved the pathway's usefulness in essentially all cancer types.